Literature DB >> 31761922

A cyotosol-selective nitric oxide bomb as a new paradigm of an anticancer drug.

Dongsik Park1, Sooseok Im, Gurusamy Saravanakumar, Yeong Mi Lee, Jinhwan Kim, Kunho Kim, Junseok Lee, Jihoon Kim, Won Jong Kim.   

Abstract

We have reported rational design of a polymeric NO delivery micelle as a cytosol-selective NO bomb. Protected NO-donors are released from the micelle under endolysosomal conditions, and then deprotected by cytosolic glutathione. Cytosol-selective NO delivery facilitates significant tumor regression without the aid of other therapeutic modalities even in intravenous administrations.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31761922     DOI: 10.1039/c9cc08028g

Source DB:  PubMed          Journal:  Chem Commun (Camb)        ISSN: 1359-7345            Impact factor:   6.222


  3 in total

Review 1.  Opportunities for Nitric Oxide in Potentiating Cancer Immunotherapy.

Authors:  Jihoon Kim; Susan N Thomas
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

2.  Lymph-Directed Self-Immolative Nitric Oxide Prodrug for Inhibition of Intractable Metastatic Cancer.

Authors:  Taejeong Kim; Jeeyeon Suh; Jihoon Kim; Won Jong Kim
Journal:  Adv Sci (Weinh)       Date:  2022-01-05       Impact factor: 17.521

3.  Thermosensitive hydrogel releasing nitric oxide donor and anti-CTLA-4 micelles for anti-tumor immunotherapy.

Authors:  Jihoon Kim; David M Francis; Lauren F Sestito; Paul A Archer; Margaret P Manspeaker; Meghan J O'Melia; Susan N Thomas
Journal:  Nat Commun       Date:  2022-03-18       Impact factor: 14.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.